MARKET

NVO

NVO

Novo-Nordisk A/S
NYSE
45.89
-0.83
-1.78%
After Hours: 45.89 0 0.00% 19:59 08/14 EDT
OPEN
46.90
PREV CLOSE
46.72
HIGH
47.05
LOW
45.75
VOLUME
10.85M
TURNOVER
--
52 WEEK HIGH
61.99
52 WEEK LOW
34.64
MARKET CAP
203.01B
P/E (TTM)
11.47
1D
5D
1M
3M
1Y
5Y
1D
Novo, LightPath, Jasper, UMAC, CCEP Trending With Analysts
TipRanks · 1d ago
Eli Lilly Just Scored Europe's First Weight Loss Pill Approval -- and the Growth Story Keeps Getting Bigger
The Motley Fool · 2d ago
Inside ARMH, STHH and ASMH: Three Semiconductor ADRhedged™ ETFs, and What the Currency Hedge Actually Added
TipRanks · 2d ago
Novo Nordisk (NVO) Sues A Rival Over Obesity Drug Advertising Claims
Simply Wall St · 2d ago
WST Q2 Beat and Raised 2026 Outlook Reinforce the HVP Growth Story
NASDAQ · 3d ago
Should Investors Buy WST as HVP Growth Meets a Premium Valuation?
NASDAQ · 3d ago
Is Novo Nordisk's Wegovy-Fueled Rebound Evaporating?
The Motley Fool · 3d ago
Novo Nordisk Completes Key Oral Semaglutide Study in Japan: What Investors Should Watch
TipRanks · 3d ago
More
About NVO
Novo Nordisk A/S is a global healthcare company engaged in diabetes care. The Company is also engaged in the discovery, development, manufacturing and marketing of pharmaceutical products. The Company operates through two business segments: diabetes and obesity care, and biopharmaceuticals. The Company's diabetes and obesity care segment covers insulin, GLP-1, other protein-related products, such as glucagon, protein-related delivery systems and needles, and oral anti-diabetic drugs. The Company's biopharmaceuticals segment covers the therapy areas of hemophilia care, growth hormone therapy and hormone replacement therapy. The Company also offers Saxenda product to treat obesity. It offers a range of products, including NovoLog/NovoRapid; NovoLog Mix/NovoMix; Prandin/NovoNorm; NovoSeven; Norditropin, and Vagifem. As of December 31, 2016, it marketed its products in over 180 countries. Its regional structure consists of two commercial units: North America and International Operations.

Webull offers Novo Nordisk A/S (ADR) stock information, including NYSE: NVO real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, NVO stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading NVO stock methods without spending real money on the virtual paper trading platform.